Compare · ARGX vs ENTX
ARGX vs ENTX
Side-by-side comparison of argenx SE (ARGX) and Entera Bio Ltd. (ENTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and ENTX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 104.9x ENTX ($603.2M).
- Over the past year, ARGX is up 44.0% and ENTX is up 75.6% - ENTX leads by 31.7 points.
- ENTX has been more active in the news (20 items in the past 4 weeks vs 11 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 0 for ENTX).
- Company
- argenx SE
- Entera Bio Ltd.
- Price
- $1019.71+0.82%
- $3.46+0.87%
- Market cap
- $63.27B
- $603.2M
- 1M return
- +14.62%
- -11.51%
- 1Y return
- +43.97%
- +75.63%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 11
- 20
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE
Latest ENTX
- SEC Form S-3 filed by Entera Bio Ltd.
- SEC Form 3 filed by new insider Camisasca Riccardo Paolo
- Entera Bio Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events
- Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
- SEC Form D filed by Entera Bio Ltd.
- Director Rubin Steven D was granted 19,117 units of Ordinary Shares, increasing direct ownership by 127% to 34,117 units (SEC Form 4)
- Director Malca Yonatan was granted 22,815 units of Ordinary Shares, increasing direct ownership by 29% to 100,231 units (SEC Form 4)
- Director Taitel Haya was granted 20,790 units of Ordinary Shares, increasing direct ownership by 21% to 119,269 units (SEC Form 4)
- Director Ellis Sean was granted 20,034 units of Ordinary Shares, increasing direct ownership by 11% to 208,132 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Yaacov-Garbeli Dana